EN
Henlius Facts
  • 2010
    Founded in Shanghai
  • Stock Code
    2696.HK
  • First Launched
    Biosimilar in China
  • 50+
    Molecules in R&D
  • 40+
    approved markets
  • Biosimilar

    We have launched 4 self-developed monoclonal antibody (mAb) biosimilars including the first Chinese biosimilar HANLIKANG (rituximab), HANQUYOU (trastuzumab) a China-developed mAb biosimilar approved in China, Europe and U.S., and HANDAYUAN (adalimumab), and HANBEITAI (bevacizumab), navigating at the forefront of Chinese biopharmaceutical industry.

  • Bio-Innovative

    We continue the momentum for a diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. We have been replenishing our innovation pipeline with HANSIZHUANG (serplulimab injection, anti-PD-1 mAb) as backbone.

  • Combo Therapy

    Adopting "Combo+Global" differentiation strategy, we have versatile in-house combination therapy portfolio with serplulimab (anti-PD-1 mAb) as backbone. Multiple clinical trials are underway (including 3 international multi-centre clinical trials). 

Comprehensive Platform
  • R & D

    Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant potential for a variety of PD-1-based immuno-oncology combination therapies. 

  • Manufacturing

    We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Our commercial capacity totals 48,000L. The fully operational sites and quality management systems are GMP-certificated by China, the EU and U.S. regulatory agencies.


  • Commercialisation

    We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of about 1500 professionals; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide. 

Read More
News
Read More
关于
複宏漢霖
生物技術
金沙js3777登录入口由复星医药与海外科学家团队于2010年2月合资组建，公司主要致力于符合全球标准的生物类似药及创新型抗体药物的研发和生产。
Read More
A Galaxy of Talents
A Galaxy of Talents
共谋发展

Henlius upholds the talent philosophy of "attracting people with visions, engaging people with rewards, cultivating people with challenges and assessing people with performance" and makes great efforts in attracting, empowering, retaining people and putting right people to right place. 

Read More
XML 地图